<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04656236</url>
  </required_header>
  <id_info>
    <org_study_id>1-10-72-251-20</org_study_id>
    <nct_id>NCT04656236</nct_id>
  </id_info>
  <brief_title>Metabolic Effects of Exogenous 3-hydroxybutyrate in Patients With Type 1 Diabetes and Healthy Controls</brief_title>
  <official_title>Metabolic Effects of Exogenous 3-hydroxybutyrate in Patients With Type 1 Diabetes and Healthy Controls</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this clinical trial is to study the metabolic effects of intravenous&#xD;
      infusion of the ketone body, 3-hydroxybutyrate (3-OHB), in patients with type 1 diabetes and&#xD;
      healthy control subjects. Moreover, the investigators plan to examine regulatory mechanisms&#xD;
      of 3-OHB that may be related to diabetic ketoacidosis.&#xD;
&#xD;
      The hypotheses are:&#xD;
&#xD;
        1. 3-OHB related inhibition of lipolysis is impaired in patients with type 1 diabetes.&#xD;
&#xD;
        2. Intravenous infusion of 3-OHB affects signaling pathways involved in the metabolic&#xD;
           regulation in patients with type 1 diabetes and healthy controls.&#xD;
&#xD;
        3. 3-OHB infusion improves cardiac function in patients with type 1 diabetes and healthy&#xD;
           controls.&#xD;
&#xD;
      The effects of 3-OHB will be investigated by isotopic tracers examinations, fat and muscle&#xD;
      biopsies and blood samples. To evaluate effects on cardiac function echocardiography will be&#xD;
      performed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Crossover design in 2 different groups, patients with type 1 diabetes and healthy controls.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Differences in lipolysis rate</measure>
    <time_frame>After 3 hours of interventions</time_frame>
    <description>Measured as differences in palmitate flux</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in protein metabolism</measure>
    <time_frame>After 3 hours of interventions</time_frame>
    <description>Measured as differences in forearm and whole body tracer kinetics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in glucose kinetics</measure>
    <time_frame>After 3 hours of interventions</time_frame>
    <description>Measured by glucose tracer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function</measure>
    <time_frame>After 2-3 hours of interventions</time_frame>
    <description>Changes in cardiac output and left ventricular ejection fraction measured by echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in signaling in muscle and adipose tissue</measure>
    <time_frame>After 1,5-3 hours of interventions</time_frame>
    <description>Western blot examinations of muscle and adipose tissue biopsies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in circulating concentrations of 3-hydroxybutyrate, glucose, free fatty acids, insulin, glucagon and C-peptide</measure>
    <time_frame>During the 3 hours intervention period</time_frame>
    <description>Blood samples</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Diabetic Ketoacidosis</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 hours of continuously intravenous infusion of 3-hydroxybutyrate.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 hours of continuously intravenous infusion of saline (NaCl).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>3-hydroxybutyrate</intervention_name>
    <description>3-hydroxybutyrate is a metabolite, produced in the human body.</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients with type 1 diabetes:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes diagnosis&#xD;
&#xD;
          -  C-peptide negative&#xD;
&#xD;
          -  19 &lt; BMI &lt; 26&#xD;
&#xD;
          -  written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Severe comorbidity&#xD;
&#xD;
          -  Regular medication apart from insulin (except over-the-counter medicines)&#xD;
&#xD;
          -  Use of long acting insulin analogues, that work &gt; 24 hours, e.g. Tresiba&#xD;
&#xD;
          -  PI finds the patient not fit (e.g. mental illness, too nervous, unacceptable screening&#xD;
             blood tests or other).&#xD;
&#xD;
        Healthy control subjects:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  19 &lt; BMI &lt; 26&#xD;
&#xD;
          -  written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Chronic disease&#xD;
&#xD;
          -  Regular medication (except over-the-counter medicines)&#xD;
&#xD;
          -  PI finds the patient not fit (e.g. mental illness, too nervous, unacceptable screening&#xD;
             blood tests or other).&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Niels MÃ¸ller, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Department of Endocrinology and Steno Diabetes Center Aarhus, Aarhus University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maj Bangshaab, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabetes Center Aarhus and Aarhus University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maj Bangshaab, MD</last_name>
    <phone>30334546</phone>
    <email>bangshaab@clin.au.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Steno diabetes center Aarhus</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maj Bangshaab, MD</last_name>
      <phone>30334546</phone>
      <email>bangshaab@clin.au.dk</email>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 30, 2020</study_first_submitted>
  <study_first_submitted_qc>November 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2020</study_first_posted>
  <last_update_submitted>January 5, 2021</last_update_submitted>
  <last_update_submitted_qc>January 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Ketosis</mesh_term>
    <mesh_term>Diabetic Ketoacidosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

